Who founded Velorum Therapeutics?

Velorum Therapeutics was founded by Pouya Modareszadeh, Parsa Modareszadeh in 2023.

Who are Velorum Therapeutics's investors?

Velorum Therapeutics's investors include Eight Capital, Metaplanet, MyAsiaVC, SciFounders, Transpose Platform Management, Y Combinator, 468 Capital, Andreessen Horowitz and 5 more.

Where is Velorum Therapeutics headquartered?

Velorum Therapeutics is headquartered in San Francisco, US.

Velorum Therapeutics

YC W24

San Francisco, US · Founded 2023 · 5 employees · 13 known investors

Find your way into Velorum Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Velorum Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

Biotech Healthtech Medical Devices Healthcare Therapeutics Drug discovery OncologyUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W24)

Velorum Therapeutics was founded in 2023 by Pouya Modareszadeh and Parsa Modareszadeh.

Pouya Modareszadeh Co-Founder & CEOPouya Modareszadeh is co-founder and CEO of Velorum Therapeutics, a company developing therapeutic medicines.

Parsa Modareszadeh Co-Founder & PresidentParsa Modareszadeh is co-founder and president of Velorum Therapeutics, where he works on drug development. He was a Goldwater Scholar.

Investors · 13

Eight Capitallisted by Eight CapitalNorwalk

How we know: Y Combinator's founder network · eightcapital.com · Not right? Tell us

Metaplanetlisted by MetaplanetTallinn · $500K – $10M

How we know: Metaplanet's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

MyAsiaVClisted by MyAsiaVCSeattlevia Aabhas Khanna · inferred

How we know: Y Combinator's founder network · Not right? Tell us

SciFounderslisted by SciFoundersSan Francisco · $1M

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Transpose Platform Managementlisted by Transpose Platform ManagementSan Francisco

How we know: Transpose Platform Management's portfolio page · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

468 CapitalreportedBerlin

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Andreessen HorowitzreportedMenlo Park · $500K – $50M

How we know: Y Combinator's founder network · Not right? Tell us

Capitalize VCreportedChicago · $100K – $200K

How we know: Y Combinator's founder network · Not right? Tell us

General Advancereported

How we know: Y Combinator's founder network · Not right? Tell us

James Beshara FundreportedVenice

How we know: Y Combinator's founder network · Not right? Tell us

Orange CollectivereportedDanville

How we know: Y Combinator's founder network · Not right? Tell us

Ritual CapitalreportedMenlo Park · $100K – $500Kvia Chris Howard · inferred

How we know: funding news · Y Combinator's founder network · Not right? Tell us

Related companies · 10

Adventris PharmaceuticalsAdventris is a biotechnology company developing cancer immunotherapy treatments.

Eris BiotechEris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

AlixiaAlixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

Epirium BioEpirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.

Notable LabsNotable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.

Alterome Therapeutics, Inc.Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

Numerion LabsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.

Orum Therapeutics Venture CapitalOrum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.

Adverum BiotechnologiesAdverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.

Mirum PharmaceuticalsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.

Companies working in the same space as Velorum Therapeutics.

Legal entities · 1

corporate structure

Velorum Therapeutics Inc.

In the news

Velorum Therapeutics: Powerful cancer drugs that starve tumorsycombinator.com · Feb 2024

Velorum Therapeutics Funding | <$5M Revenue | Complete Analysis | Extruct AIextruct.ai

Frequently asked questions

What does Velorum Therapeutics do?: Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
Who founded Velorum Therapeutics?: Velorum Therapeutics was founded by Pouya Modareszadeh, Parsa Modareszadeh in 2023.
Who are Velorum Therapeutics's investors?: Velorum Therapeutics's investors include Eight Capital, Metaplanet, MyAsiaVC, SciFounders, Transpose Platform Management, Y Combinator, 468 Capital, Andreessen Horowitz and 5 more.
Where is Velorum Therapeutics headquartered?: Velorum Therapeutics is headquartered in San Francisco, US.